Blood Conservation Using Tranexamic Acid Is Not Superior to Epsilon-Aminocaproic Acid after Total Knee Arthroplasty

Journal of Bone and Joint Surgery - American Volume

Volumn 99, Issue 19, 2017, Pages 1621-1628

  Boese, Clifford Kent ^a   Centeno, Leslie ^a   Walters, Ryan W ^a,b  

^a Heartland Oncology/Hematology   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; CREATININE; HEMOGLOBIN; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD CONSERVATION; BLOOD TRANSFUSION; COMMUNITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITAL; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURGEON; TOTAL KNEE ARTHROPLASTY; VERY ELDERLY; ADVERSE EFFECTS; BLOOD LOSS, SURGICAL; DOUBLE BLIND PROCEDURE; JOINT DISEASES; KNEE REPLACEMENT; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE;

ADULT; AGED; AGED, 80 AND OVER; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD LOSS, SURGICAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JOINT DISEASES; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; TRANEXAMIC ACID;

EID: 85031698699     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.16.00738     Document Type: Article

References (30)

1. Benoni G, Fredin H. Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomized, doubleblind study of 86 patients. J Bone Joint Surg Br. 1996; 78(3): 434-40.
2. Ortega-Andreu M, Pérez-Chrzanowska H, Figueredo R, Gómez-Barrena E. Blood loss control with two doses of tranexamic acid in amultimodal protocol for total knee arthroplasty. Open Orthop J. 2011 Mar 16;5:44-8.
3. Levine BR, Haughom B, Strong B, Hellman M, Frank RM. Blood management strategies for total knee arthroplasty. J Am Acad Orthop Surg. 2014 Jun;22 (6):361-71.
4. Camarasa MA, Ollé G, Serra-Prat M, Martín A, Sánchez M, Ricós P, Pérez A, Opisso L. Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial. Br J Anaesth. 2006 May;96 (5):576-82. Epub 2006 Mar 10.
5. Falana O, Patel G. Efficacy and safety of tranexamic acid versus e-aminocaproic acid in cardiovascular surgery. Ann Pharmacother. 2014 Dec;48(12):1563-9. Epub 2014 Sep 11.
6. Gandhi R, Evans HM, Mahomed SR, Mahomed NN. Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis. BMC Res Notes. 2013 May 7;6(1):184.
7. Pachauri A, Acharya KK, Tiwari AK. The effect of tranexamic acid on hemoglobin levels during total knee arthroplasty. Am J Ther. 2014 Sep-Oct;21(5):366-70.
8. Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res. 2009 Mar;123 (5):687-96. Epub 2008 Nov 12.
9. Maniar RN, Kumar G, Singhi T, Nayak RM, Maniar PR. Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. Clin Orthop Relat Res. 2012 Sep;470(9):2605-12. Epub 2012 Mar 15.
10. Ray M, Hatcher S, Whitehouse SL, Crawford S, Crawford R. Aprotinin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty-a prospective randomized double-blind placebo-controlled study. J Thromb Haemost. 2005 Jul;3(7):1421-7.
11. Oppenheimer AJ, Ranganathan K, Levi B, Strahle JM, Kapurch J, Muraszko KM, Buchman SR. Minimizing transfusions in primary cranial vault remodeling: the role of aminocaproic acid. J Craniofac Surg. 2014 Jan;25(1):82-6.
12. Martin K, Knorr J, Breuer T, Gertler R, Macguill M, Lange R, Tassani P, Wiesner G. Seizures after open heart surgery: comparison of e-aminocaproic acid and tranexamic acid. J Cardiothorac Vasc Anesth. 2011 Feb;25(1):20-5.
13. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs. 1985 Mar;29(3):236-61.
14. American Society of Anesthesiologists. ASA physical status classification system. 2014. https://www.asahq.org/resources/clinical-information/asa-physicalstatus- classification-system. Accessed 2017 April 3.
15. Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962 Feb;51(2):224-32.
16. Brecher ME, Monk T, Goodnough LT. A standardized method for calculating blood loss. Transfusion. 1997 Oct;37(10):1070-4.
17. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70(3):659-63.
18. DeMets DL, Lan KKG. Interim analysis: the alpha spending function approach. Stat Med. 1994 Jul 15-30;13(13-14):1341-52; discussion 1353-6.
19. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64(2):191-9.
20. Lecker I, Orser BA, Mazer CD. "Seizing" the opportunity to understand antifibrinolytic drugs. Can J Anaesth. 2012 Jan;59(1):1-5. Epub 2011 Nov 4.
21. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, Ker K. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011;1CD001886.
22. Eubanks JD. Antifibrinolytics in major orthopaedic surgery. J Am Acad Orthop Surg. 2010 Mar;18(3):132-8.
23. Henry D, Carless P, Fergusson D, Laupacis A. The safety of aprotinin and lysinederived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ. 2009 Jan 20;180(2):183-93. Epub 2008 Dec 2.
24. Makhija N, Sarupria A, Kumar Choudhary S, Das S, Lakshmy R, Kiran U. Comparison of epsilon aminocaproic acid and tranexamic acid in thoracic aortic surgery: clinical efficacy and safety. J Cardiothorac Vasc Anesth. 2013 Dec;27(6):1201-7. Epub 2013 Sep 17.
25. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg. 2010 Feb 1;110(2):350-3. Epub 2009 Dec 8.
26. Alshryda S, Sarda P, Sukeik M, Nargol A, Blenkinsopp J, Mason JM. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br. 2011 Dec;93(12):1577-85.
27. Yang ZG, Chen WP, Wu LD. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Joint Surg Am. 2012 Jul 3;94(13):1153-9.
28. Harley BJ, Beaupré LA, Jones CA, Cinats JG, Guenther CR. The effect of epsilon aminocaproic acid on blood loss in patients who undergo primary total hip replacement: a pilot study. Can J Surg. 2002 Jun;45(3):185-90.
29. Breda JR, Gurian DB, Breda ASCR, Meneghine A, Freitas AC, Matos LL, Abreu LC, Pires AC. Topical use of antifibrinolytic agent to reduce postoperative bleeding after coronary artery bypass surgery. Rev Bras Cir Cardiovasc. 2009 Jul-Sep;24 (3):341-5.
30. Gurian DB, Meneghini A, Abreu LC, Murad N, Matos LL, Pires AC, Valenti VE, Breda JR. A randomized trial of the topical effect of antifibrinolytic epsilon aminocaproic acid on coronary artery bypass surgery without cardiopulmonary bypass. Clin Appl Thromb Hemost. 2014 Sep;20(6):615-20. Epub 2013 Feb 22.